The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link Development of 503B Bulks List FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT Is BPC 157 Banned? Oral vs. Injectable Forms Explained